FDA Grants Accelerated Approval to New Treatment for Head and Neck Cancer
The U.S. Food and Drug Administration granted accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell
The U.S. Food and Drug Administration granted accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell